Two-round allele specific-polymerase chain reaction: A simple and highly sensitive method for JAK2V617F mutation detection

Clinica Chimica Acta

Volumn 401, Issue 1-2, 2009, Pages 148-151

  Kannim, Supattra ^a   Thongnoppakhun, Wanna ^a   Auewarakul, Chirayu U ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

AS PCR; DHPLC; JAK2 mutation detection; Myeloproliferative disorders; RFLP; Sequencing

Indexed keywords

JANUS KINASE 2;

ALLELE; ALLELE SPECIFIC POLYMERASE CHAIN REACTION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DILUTION; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MYELOPROLIFERATIVE DISORDER; NUCLEIC ACID ANALYSIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS;

ALLELES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SENSITIVITY AND SPECIFICITY;

EID: 58849163658     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.12.010     Document Type: Article

References (20)

1. Vardiman J.W., Brunning R.D., and Harris N.L. Chronic myeloproliferative diseases: introduction. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France 17-19
2. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005) 1144-1148
3. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
4. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., Passweg J.R., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
5. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005) 387-397
6. Zhao R., Xing S., Li Z., Fu X., Li Q., Krantz S.B., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 280 (2005) 22788-22792
7. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., and Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 107 (2006) 4274-4481
8. Tefferi A., Thiele J., Orazi A., Kvasnicka H.M., Barbui T., Hanson C.A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110 (2007) 1092-1097
9. Lippert E., Boissinot M., Kralovics R., Girodon F., Dobo I., Praloran V., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108 (2006) 1865-1867
10. Lay M., Mariappan R., Gotlib J., Dietz L., Sebastian S., Schrijver I., et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 8 (2006) 330-334
11. Olsen R.J., Tang Z., Farkas D.H., Bernard D.W., Zu Y., and Chang C.C. Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch Pathol Lab Med 130 (2006) 997-1003
12. Sattler M., Walz C., Crowley B.J., Lengfelder E., Janne P.A., Rogers A.M., et al. A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood 107 (2006) 1237-1238
13. Tefferi A., Lasho T.L., Schwager S.M., Steensma D.P., Mesa R.A., Li C.Y., et al. The JAK2 (V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol 131 (2005) 320-328
14. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
15. Jones A.V., Kreil S., Zoi K., Waghorn K., Curtis C., Zhang L., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
16. Chen Q., Lu P., Jones A.V., Cross N.C., Silver R.T., and Wang Y.L. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn 9 (2007) 272-276
17. Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13 (2008) 311-320
18. Verstovsek S., Kantarjian H.M., Pardanani A., Thomas D.A., Cortes J.E., Mesa R., et al. A phase I/II Study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia mylofibrosis (Post-PV/ET MF). J Clin Oncol 26 (2008) suppl; abstr 7004
19. Udomsakdi-Auewarakul C., Visuthisakchai S., Sangruchi T., and Issaragrisil S. Reversal of marrow fibrosis in agnogenic myeloid metaplasia by allogeneic peripheral blood stem cell transplantation. Asian Pac J Allergy Immunol 21 (2003) 121-126
20. Barosi G., and Bacigalupo A. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Curr Opin Hematol 13 (2006) 74-78